OCULAR THERAPEUTIX, INC Comprehensive Income
OCULAR THERAPEUTIX, INC (OCUL) reported Comprehensive Income of -$86.37 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2020-03-12
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-12-31 was -$17.40M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-09-30 was -$15.01M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-06-30 was -$13.80M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-03-31 was -$13.77M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$86.37M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$59.98M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$63.38M.
- OCULAR THERAPEUTIX, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$44.64M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$86.37M 10-K · filed 2020-03-12 | |||
| 2018-12-31 | -$17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$32.41M derived: sum of 2 quarters · filed 2020-03-12 | -$46.21M derived: sum of 3 quarters · filed 2020-03-12 | -$59.98M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$15.01M 10-Q · filed 2018-11-07 | -$28.81M derived: sum of 2 quarters · filed 2018-11-07 | -$42.58M 10-Q · filed 2018-11-07 | -$55.68M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$13.80M 10-Q · filed 2018-08-07 | -$27.57M 10-Q · filed 2018-08-07 | -$40.67M derived: sum of 3 quarters · filed 2020-03-12 | -$56.24M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$13.77M 10-Q · filed 2018-05-08 | -$26.87M derived: sum of 2 quarters · filed 2020-03-12 | -$42.43M derived: sum of 3 quarters · filed 2020-03-12 | -$61.12M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$28.67M derived: sum of 2 quarters · filed 2020-03-12 | -$47.35M derived: sum of 3 quarters · filed 2020-03-12 | -$63.38M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$15.57M 10-Q · filed 2018-11-07 | -$34.25M derived: sum of 2 quarters · filed 2018-11-07 | -$50.28M 10-Q · filed 2018-11-07 | -$63.11M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | -$18.68M 10-Q · filed 2018-08-07 | -$34.71M 10-Q · filed 2018-08-07 | -$47.54M derived: sum of 3 quarters · filed 2019-03-07 | -$57.15M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$16.03M 10-Q · filed 2018-05-08 | -$28.86M derived: sum of 2 quarters · filed 2019-03-07 | -$38.46M derived: sum of 3 quarters · filed 2019-03-07 | -$49.90M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | -$12.83M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$22.43M derived: sum of 2 quarters · filed 2019-03-07 | -$33.87M derived: sum of 3 quarters · filed 2019-03-07 | -$44.64M 10-K · filed 2019-03-07 |
| 2016-09-30 | -$9.60M 10-Q · filed 2017-11-07 | -$21.04M derived: sum of 2 quarters · filed 2017-11-07 | -$31.81M 10-Q · filed 2017-11-07 | -$42.50M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$11.44M 10-Q · filed 2016-08-09 | -$22.21M 10-Q · filed 2017-08-08 | -$32.90M derived: sum of 3 quarters · filed 2018-03-08 | -$44.43M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$10.77M 10-Q · filed 2017-05-05 | -$21.46M derived: sum of 2 quarters · filed 2018-03-08 | -$32.99M derived: sum of 3 quarters · filed 2018-03-08 | -$43.01M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$22.22M derived: sum of 2 quarters · filed 2018-03-08 | -$32.24M derived: sum of 3 quarters · filed 2018-03-08 | -$39.82M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$11.53M 10-Q · filed 2016-11-09 | -$21.55M derived: sum of 2 quarters · filed 2016-11-09 | -$29.13M 10-Q · filed 2016-11-09 | -$37.08M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | -$10.02M 10-Q · filed 2016-08-09 | -$17.59M 10-Q · filed 2016-08-09 | -$25.55M derived: sum of 3 quarters · filed 2017-03-10 | -$32.84M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$7.58M 10-Q · filed 2016-05-10 | -$15.53M derived: sum of 2 quarters · filed 2017-03-10 | -$22.83M derived: sum of 3 quarters · filed 2017-03-10 | -$29.22M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$15.25M derived: sum of 2 quarters · filed 2017-03-10 | -$21.64M derived: sum of 3 quarters · filed 2017-03-10 | -$28.65M 10-K · filed 2017-03-10 |
| 2014-09-30 | -$7.29M 10-Q · filed 2015-11-10 | -$13.69M derived: sum of 2 quarters · filed 2015-11-10 | -$20.69M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | -$6.39M 10-Q · filed 2015-08-10 | -$13.41M 10-Q · filed 2015-08-10 | ||
| 2013-12-31 | -$13.32M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |